Transfusion of Prematures Trial

NICHD Neonatal Research Network1,824 enrolled

Overview

The objective of the TOP trial is to determine whether higher hemoglobin thresholds for transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months of age, using standardized assessments by Bayley.

Long-term outcomes of extremely low birth weight (ELBW) preterm infants, those weighing less than or equal to 1000 g at birth, are poor and pose a major health care burden. Virtually all of these infants are transfused, but at inconsistent hemoglobin (Hgb) thresholds. The investigators propose in TOP to randomize infants less than or equal to 1000 g BW and gestational age at least 22 weeks but less than 29 weeks to receive red blood cell (RBC) transfusions according to one of two strategies of Hgb thresholds, either a high Hgb (liberal transfusion) or a low Hgb (restrictive transfusion) algorithm. It is currently unknown which transfusion strategy is superior. TOP is powered to demonstrate which strategy reduces the primary outcome of death or neurodisability in survivors at 22-26 months. A secondary study entitled "Effect of Blood Transfusion Practices on Cerebral and Somatic Oximetry", also known as the NIRS study, will determine differences in cerebral oxygenation and fractional tissue oxygen extraction with NIRS between high and low hemoglobin threshold groups during red blood cell transfusions. The investigators also propose to determine whether abnormal cerebral NIRS measures are a better predictor of NDI than hemoglobin alone and whether abnormal mesenteric NIRS measures are associated with the development of NEC within the 48 hours following a transfusion. A secondary study entitled "Economic Evaluation Ancillary to the Transfusion of Prematures Randomized Controlled Trial" will determine whether higher transfusion threshold will result in lower total costs to society over the first 22 to 26 corrected months of life and estimate the incremental cost-effectiveness ratio for survival without neurodevelopmental impairment, from the perspective of society, the third-party payer, and the family. Extended follow-up: Subjects will be seen for a follow-up visit at 5-6 years corrected age to assess neurological and functional outcomes at early school age based on neonatal transfusion threshold.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

1,824

Conditions

Infant, Newborn, Diseases Infant, Extremely Low Birth Weight Infant, Small for Gestational Age Bronchopulmonary Dysplasia (BPD)Anemia

Interventions

Liberal Cell TransfusionPROCEDURE

Restricted red cell transfusionPROCEDURE

Eligibility

Sex: ALLMax age: 48 Hours

Medical Language ↔ Plain English

Inclusion Criteria: * Birth weight less than or equal to 1000 grams. * Gestational age at least 22 weeks but less than 29 weeks * Admitted to the NICU within 48 hours of life Exclusion Criteria: * Considered nonviable by the attending neonatologist * Cyanotic congenital heart disease * Parents opposed to the transfusion of blood * Parents with hemoglobinopathy or congenital anemia * In-utero fetal transfusion * Twin-to-twin transfusion syndrome * Isoimmune hemolytic disease * Lack of parental consent * Severe acute hemorrhage, acute shock, sepsis with coagulopathy, or need for perioperative transfusion. * Prior blood transfusion on clinical grounds beyond the first 6 hours of life * Infant has received erythropoietin prior to randomization, or is intended to receive erythropoietin through the neonatal course * Congenital condition, other than premature birth, that adversely affects life expectancy or neurodevelopment. * High probability that the family is socially disorganized to the point of being unable to attend follow-up at 22-26 months.

Locations (20)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Outcomes

Primary Outcomes

Death or Neurodevelopmental Impairment

A composite outcome that measures the occurrence of death or neurodevelomental impairment between birth and 22-26 months corrected age.

Time frame: Birth to 22-26 months corrected age

Death

This is measured as Yes if an infant died between birth and 22-26 months corrected age; Otherwise, No.

Time frame: Birth to 22-26 months corrected age

Neurodevelopmental Impairment

This is measured as Yes if any hearing impairment or visual impairment is noted, if severe or moderate cerebral palsy is noted, or if the cognitive score of the Bayley III score is more than 1 standard deviation below the average; Otherwise, No.

Time frame: at 22-26 months corrected age

Cognitive Delay

This is measured as Yes if the Bayley Scale of Infant and Toddler Development (BSID)-III cognitive score is more than 1 standard deviation below the average; Otherwise, No.

Time frame: at 22-26 months corrected age

Moderate or Severe Cerebral Palsy

This is measured as Yes if the Gross Motor Function Classification System (GMFCS) score is level II or higher; Otherwise, No. Higher values of the GMFCS are worse than lower values; a level of "I" denotes mild cerebral palsy (CP); level "II" or "III" moderate CP; level "IV" or "V" severe CP.

Time frame: at 22-26 months corrected age

Severe Vision Impairment

This is measured as Yes if the corrected visual acuity in the better eye of less than 20/200; Otherwise, No.

Time frame: at 22-26 months corrected age

Severe Hearing Impairment

This is measured as Yes if bilateral hearing loss occurred for which hearing aids or cochlear implants were warranted; Otherwise, No.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Survival to Discharge Without Severe Complications

This is measured as Yes if survived to discharge without severe morbidity, defined as bronchopulmonary dysplasia, retinopathy of prematurity (stage 3 or higher or requiring treatment), or serious brain abnormality; Otherwise, No.

Time frame: Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)

Bronchopulmonary Dysplasia, Diagnosed on the Basis of the Need for Supplemental Oxygen After a Standardized Oxygen Reduction Test at 36 Weeks of Postmenstrual Age

This is measured as Yes if experienced bronchopulmonary dysplasia, diagnosed on the basis of the need for supplemental oxygen after a standardized oxygen reduction test at 36 weeks of postmenstrual age; Otherwise, No.

Time frame: at 36 weeks postmenstrual age

Retinopathy of Prematurity Stage >=3 or Treatment for That Condition Received

This is measured as Yes if experienced Retinopathy of Prematurity (ROP) Stage \>=3 or received treatment for that condition; Otherwise, No. Higher stages of ROP indicate a worse outcome; the stages range from 1 for "mild" disease, to 5 for "severe" disease.

Time frame: Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)

Grade 3 or 4 Intraventricular Hemorrhage, Cystic Periventricular Leukomalacia, or Ventriculomegaly Diagnosed on Ultrasonographic Examination

This is measured as Yes if experienced Grade 3 or 4 intraventricularhemorrhage, cystic periventricular leukomalacia, or ventriculomegaly diagnosed on ultrasonographic examination; Otherwise, No.

Time frame: Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)

Necrotizing Enterocolitis, Bell's Stage >=2

This is measured as Yes if experienced necrotizing enterocolitis (NEC), Bell's stage \>=2; Otherwise, No. Higher scores of Bell's staging criteria denote a worse outcome, where "1" denotes suspect, "2" definite and "3" advanced NEC.

Time frame: Birth to initial hospital discharge or to death if it occurs earlier (a median of 97 days)

Number of Transfusions Per Infant

This is measured as the number of protocol compliant transfusions, clinically justified non-protocol transfusions and unjustified non-protocol transfusions (violations)

Time frame: Birth, up to the earliest of: death, hospital discharge, or 36 weeks postmenstrual age (PMA)

Weight-for-age: Z-score

This is measured as the weight-for-age Z-score at 36 weeks postmenstrual age or at initial hospital discharge, whichever occurs first. The Z-score is determined using Olsen percentile curves, and is derived from a normal distribution, where 0 designates average weight-for-age, and negative scores denote less than average weight-for-age.

Time frame: at 36 weeks postmenstrual age or initial hospital discharge, whichever occurs first

Length-for-age: Z-score

This is measured as the length-for-age Z-score at 36 weeks postmenstrual age or at initial hospital discharge, whichever occurs first. The Z-score is determined using Olsen percentile curves, and is derived from a normal distribution, where 0 designates average length-for-age, and negative scores denote less than average length-for-age.

Time frame: at 36 weeks postmenstrual age or initial hospital discharge, whichever occurs first

Head Circumference-for-age: Z-score

This is measured as the head circumference-for-age Z-score at 36 weeks postmenstrual age or at initial hospital discharge, whichever occurs first. The Z-score is determined using Olsen percentile curves, and is derived from a normal distribution, where 0 designates average head circumference-for-age, and negative scores denote less than average head circumference-for-age.

Time frame: at 36 weeks postmenstrual age or initial hospital discharge, whichever occurs first

Postmenstrual Age at Final Trachael Extubation

This is measured as the average postmenstrual age (in weeks) at final tracheal extubation in infants who were intubated.

Time frame: at final trachael extubation, assessed from birth up to the earliest of: death, hospital discharge, or 36 weeks postmenstrual age

Postmenstrual Age at Final Caffeine Dose in Infants Who Received Caffeine Treatment

This is measured as the average postmenstrual age (in weeks) at final caffeine dose in infants who received caffeine treatment.

Time frame: at final caffeine dose, assessed from birth up to the earliest of: death, hospital discharge, or 36 weeks postmenstrual age

Length of Stay

This is measured as the length of stay (in days) up to initial hospital discharge or death, whichever occurred first.

Time frame: at initial hospital discharge or at death if it occurs earlier (a median of 97 days)

Time to Full Enteral Feeding

This is measured as the amount of days it took for full enteral feeding to occur.

Time frame: at first full enteral feeding, assessed from birth up to initial hospital discharge or to death if it occurs earlier (a median of 97 days)

Severe Cerebral Palsy

This is measured as Yes if Gross Motor Function Classification System (GMFCS) is levels IV or V; Otherwise, No. Higher values of the GMFCS are worse than lower values; a level of "I" denotes mild cerebral palsy (CP); level "II" or "III" moderate CP; level "IV" or "V" severe CP.

Time frame: at 22-26 months corrected age

Hydrocephalus Shunt

This is measured as Yes if experienced Hydrocephalus shunt by follow-up; Otherwise, No.

Time frame: Initial hospital discharge to 22-26 months corrected age

Microcephaly

This is measured as a head circumference-for-age Z-score of less than -2; Otherwise, No. The Z-score is determined using WHO percentile curves, and is derived from a normal distribution, where 0 designates average head circumference-for-age, and negative scores denote less than average head circumference-for-age.

Time frame: at 22-26 months corrected age

Seizure Disorder

This is measured as Yes if experienced one or more seizures since discharge or of regular use of anticonvulsants or seizure medications; Otherwise, No.

Time frame: Initial hospital discharge to 22-26 months corrected age

Respiratory Disease Necessitating Readmission Before Follow-up

This is measured as Yes if obtained Respiratory disease necessitating readmission before follow-up; Otherwise, No.

Time frame: Initial hospital discharge to 22-26 months corrected age

Composite Language Score Less Than 85

This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite language score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100.

Time frame: at 22-26 months corrected age

Composite Motor Score Less Than 85

This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite motor score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100.

Time frame: at 22-26 months corrected age

Composite Cognitive Score Less Than 70

This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite cognitive score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100.

Time frame: at 22-26 months corrected age

Composite Language Score Less Than 70

This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite language score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100.

Time frame: at 22-26 months corrected age

Composite Motor Score Less Than 70

This is measured as Yes if scored less than 85 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite motor score; Otherwise, No. Higher scores indicate better performance. Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100.

Time frame: at 22-26 months corrected age